by John A. Jenkins | Jan 10, 2024 | Antitrust, FOIA, FTC, Law Firms, Litigation
Requests in FOIAengine Show Groups Watching the FTC When the Federal Trade Commission joined the Justice Department last month in announcing new merger guidelines, two years in the making, the revised rules of the road were a warning to acquisitive corporations: ...
by John A. Jenkins | Jan 3, 2024 | FDA, FOIA, Pharmaceuticals
FOIAengine Lines Up the Players in a Huge Patent Fight When the Food and Drug Administration announced three weeks ago the approval of two milestone treatments for sickle cell disease, the agency hailed the action as “an innovative advancement in the field of gene...
by John A. Jenkins | Dec 6, 2023 | FOIA, SEC, Short-Selling, Stock Market
Another Short Seller Hits FOIAengine’s Radar It gets our attention when a short seller hits FOIAengine’s radar for the first time. This week, we’re talking about Nathan Koppikar – Nate, for short – and his impactful short-seller fund, Orso Partners. Orso means “bear”...
by John A. Jenkins | Nov 29, 2023 | FOIA, Politics, SEC
FOIAengine Finds SEC Chair in a Harsh Spotlight You’ve probably seen Rep. Patrick McHenry (R-NC), whether you know it or not. For a few weeks last month, he was one of the most recognizable, least known lawmakers on Capitol Hill. Professorial mien. Bow tie. Cool...
by John A. Jenkins | Nov 2, 2023 | FDA, FOIA, Pharmaceuticals
In FOIAengine, Media Requests Seek the Answer When word leaked in late August that the Department of Health and Human Services recommended that marijuana should no longer be considered a dangerous drug, media organizations quickly responded with a flurry of Freedom of...
